MedTrace Logo

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

NCT02380274 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1030

Last updated 2024-11-20

No results posted yet for this study

Summary

The purpose of this study is to describe patterns of care in CRPC patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management.

This study will also describe factors influencing treatment decisions including reason(s) for treatment choices and triggers for treatment changes for CRPC as well as describe clinical outcomes based on patient characteristics.

Conditions

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Astellas Pharma Global Development, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · APGD, Medical Affairs, Americas

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-27
Primary Completion
2021-01-14
Completion
2021-01-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02380274 on ClinicalTrials.gov